Neval E Wareham1, Qiuju Li2, Henrik Sengeløv3, Caspar Da Cunha-Bang4, Finn Gustafsson4, Carsten Heilmann5, Michael Perch4, Allan Rasmussen6, Søren Schwartz Sørensen7, Amanda Mocroft2, Jens D Lundgren8. 1. CHIP, Department of Infectious Diseases, Centre for Cardiac, Pulmonary and Infectious Diseases Vascular, University of Copenhagen, Rigshospitalet, Section 2100, Blegdamsvej 9, 2100 Copenhagen, Copenhagen Ø, Denmark. neval.ete.wareham@regionh.dk. 2. Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), University College London, London, UK. 3. Department of Haematology, Rigshospitalet, Copenhagen, Denmark. 4. Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. 5. Department of Paediatrics, Rigshospitalet, Copenhagen, Denmark. 6. Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark. 7. Department of Nephrology, Rigshospitalet, Copenhagen, Denmark. 8. CHIP, Department of Infectious Diseases, Centre for Cardiac, Pulmonary and Infectious Diseases Vascular, University of Copenhagen, Rigshospitalet, Section 2100, Blegdamsvej 9, 2100 Copenhagen, Copenhagen Ø, Denmark.
Abstract
PURPOSE: Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof. METHODS: Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression. RESULTS: During a median of 3.4 (IQR 1.3-6.4) and 2.6 (0.8-5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0-4.3) and 2.2 (1.6-3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4-25.7) and 25.4 (5.1-126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8-3.4) and 2.3 (1.4-3.9), resp.), but neither with prior cancer nor type of immunosuppressants. CONCLUSION: Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.
PURPOSE: Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof. METHODS: Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression. RESULTS: During a median of 3.4 (IQR 1.3-6.4) and 2.6 (0.8-5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0-4.3) and 2.2 (1.6-3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4-25.7) and 25.4 (5.1-126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8-3.4) and 2.3 (1.4-3.9), resp.), but neither with prior cancer nor type of immunosuppressants. CONCLUSION: Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.
Authors: Sarah C Markt; Jennifer R Rider; Kathryn L Penney; Fredrick R Schumacher; Mara M Epstein; Katja Fall; Howard D Sesso; Meir J Stampfer; Lorelei A Mucci Journal: Prostate Date: 2014-05-20 Impact factor: 4.104
Authors: Sandahl H Nelson; Theodore M Brasky; Ruth E Patterson; Gail A Laughlin; Donna Kritz-Silverstein; Beatrice J Edwards; Dorothy Lane; Thomas E Rohan; Gloria Y F Ho; JoAnn E Manson; Andrea Z LaCroix Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-14 Impact factor: 4.254
Authors: C Ekenberg; I P Lodding; N E Wareham; S S Sørensen; H Sengeløv; F Gustafsson; A Rasmussen; M Perch; J D Lundgren; M Helleberg Journal: Eur J Clin Microbiol Infect Dis Date: 2017-08-08 Impact factor: 3.267
Authors: Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich Journal: BMJ Date: 2010-02-11
Authors: J Douglas Rizzo; Rochelle E Curtis; Gérard Socié; Kathleen A Sobocinski; Ethel Gilbert; Ola Landgren; Lois B Travis; William D Travis; Mary E D Flowers; Debra L Friedman; Mary M Horowitz; John R Wingard; H Joachim Deeg Journal: Blood Date: 2008-10-29 Impact factor: 22.113
Authors: J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: Maria Raffaella Petrara; Sarah Shalaby; Elena Ruffoni; Martina Taborelli; Francesco Carmona; Silvia Giunco; Paola Del Bianco; Pierluca Piselli; Diego Serraino; Umberto Cillo; Riccardo Dolcetti; Patrizia Burra; Anita De Rossi Journal: Front Oncol Date: 2022-06-13 Impact factor: 5.738
Authors: Ranya Abdulovski; Dina L Møller; Andreas D Knudsen; Søren S Sørensen; Allan Rasmussen; Susanne D Nielsen; Neval E Wareham Journal: Eur J Haematol Date: 2022-07-14 Impact factor: 3.674